Acer therapeutics announces topline results from acer-801 (osanetant) phase 2a trial

Acer-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women acer-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women
ACER Ratings Summary
ACER Quant Ranking